CXCL12 expression in malignant mesothelioma Source: Eur Respir J 2007; 30: Suppl. 51, 138s Year: 2007
Clinical characteristics, treatment and survival outcomes in malignant mesothelioma Source: Annual Congress 2012 - Diagnosis and biology of malignant pleural effusions Year: 2012
Malignant pleural mesothelioma: new treatment modalities Source: Annual Congress 2005 - Clinical year in review Year: 2005
The clinical effect and expression of alpha-methylacyl-CoA racemace (AMACR) in the differential diagnosis of malign mesothelioma and adenocarcinoma of lung Source: Annual Congress 2012 - New aspects of lung cancer biology Year: 2012
Evaluating the role of muc4 expression in the differential diagnosis of mesothelioma and adenocarcinoma of the lung Source: Eur Respir J 2006; 28: Suppl. 50, 81s Year: 2006
Prognostic value of treatment outcomes patients with malignant pleural mesothelioma Source: Annual Congress 2010 - Current issues in malignant pleural diseases Year: 2010
Is there any advantage of chemotherapy on survival of patients with diffuse malignant pleural mesothelioma? Source: Eur Respir J 2003; 22: Suppl. 45, 29s Year: 2003
The presence of human mammaglobin transcripts in the pleural effusion is not predictive of survival in patients with malignant mesothelioma Source: Annual Congress 2008 - Biology in thoracic tumours Year: 2008
Survival prognosis and target therapy best response in adenocarcinoma lung cancer pts with mutation EGFR gene Source: Annual Congress 2009 - Treatment of lung cancer Year: 2009
The impact of multimodal treatment approaches in patients with malignant pleural mesothelioma Source: Annual Congress 2010 - Diagnostic and therapeutic problems in surgical oncology Year: 2010
KRAS & TP53 mutations cause malignant mesothelioma Source: ERS Lung Science Conference 2017 Year: 2017
Malignant pleural mesothelioma (MPM): clinical presentation, complications and survival Source: Eur Respir J 2002; 20: Suppl. 38, 272s Year: 2002
BAP1 loss predicts longer survival for mesothelioma patients treated with pemetrexed-based chemotherapy. Source: Virtual Congress 2020 – Malignant pleural effusion in 2020: understanding the biology and clinical implications Year: 2020
Treatment of malignant pleural mesothelioma with caelyx: few responses but good survival Source: Eur Respir J 2004; 24: Suppl. 48, 526s Year: 2004
Satisfractory therapeutic effects of EGFR-TK treatment of a malignant mesothelioma of the pleura: a case report Source: Eur Respir J 2003; 22: Suppl. 45, 30s Year: 2003
Malignant mesothelioma and chemotherapy: efficacy and influence on survival of patients Source: Eur Respir J 2002; 20: Suppl. 38, 272s Year: 2002
The role of P53 tumor suppressor gene mutations in early diagnosis of lung cancer among patients with solitary pulmonary nodule Source: Annual Congress 2009 - Pathogenesis of lung cancer Year: 2009
Prognostic impact of histology and treatment modalities in malignant mesothelioma Source: Annual Congress 2013 –Clinical problems in mediastinal and pleural malignacies Year: 2013
Expression of human mammaglobin gene in pleural effusion of patients affected by malignant pleural mesothelioma (MM) Source: Eur Respir J 2004; 24: Suppl. 48, 81s Year: 2004
Survival outcomes of patients diagnosed with lung adenocarcinoma with ALK gene rearrangement Source: Virtual Congress 2021 – Therapy of lung cancer Year: 2021